Search research articles
Contact Us
Filters
Showing results (591-600 of 704) with videos related to
Page
of 71
Sort By:
International Journal of Cancer
|
September 5, 2018
Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility
James S Wilmott, Peter A Johansson, Felicity Newell, et al.
Cancer Discovery
|
April 30, 2017
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
Banu Eskiocak, Elizabeth A McMillan, Saurabh Mendiratta, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 5, 2024
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Mario Mandalà, Andrea Ferrari, Ines B Brecht, et al.
The Lancet. Oncology
|
May 14, 2021
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Ines Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
M T Tetzlaff, J L Messina, J E Stein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 12, 2025
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
Mario Mandalà, Teresa Amaral, Piotr Rutkowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
British Journal of Cancer
|
October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Prachi Bhave, Lalit Pallan, Georgina V Long, et al.
Page
of 71
Search research articles
Search
Showing results (591-600 of 704) with videos related to
Sort By:
Page
of 71
International Journal of Cancer
|
September 5, 2018
Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility
James S Wilmott, Peter A Johansson, Felicity Newell, et al.
Cancer Discovery
|
April 30, 2017
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
Banu Eskiocak, Elizabeth A McMillan, Saurabh Mendiratta, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 5, 2024
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Mario Mandalà, Andrea Ferrari, Ines B Brecht, et al.
The Lancet. Oncology
|
May 14, 2021
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Ines Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
M T Tetzlaff, J L Messina, J E Stein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 12, 2025
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
Mario Mandalà, Teresa Amaral, Piotr Rutkowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
British Journal of Cancer
|
October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Prachi Bhave, Lalit Pallan, Georgina V Long, et al.
Page
of 71